In melanoma patients, dual BRAF/MEK inhibition has become standard of care treatment for BRAFV600E/K positive patients due to the prolonged tumor response compared to BRAF inhibitor monotherapy23. This evidence concerns the gene MAP2K7 and neoplasm.